JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. The invitation-only event will c ...

Core Economic Terms - Jupiter Neurosciences, Inc. has deferred the commencement of repayment for its financing to April 1, 2026, while the core economic terms of the $6.0 million financing remain unchanged [1][2][8] - The amendment does not introduce new pricing provisions, reset features, or additional financing commitments, focusing solely on installment timing and application mechanics [2] Strategic Alignment - The amendment reflects a strategic decision between Jupiter and Yorkville, demonstrating Yorkville's commitment to Jupiter's long-term strategy by adjusting installment timing without altering pricing or other economic terms [3] - This alignment allows the company to focus on advancing its Phase II Parkinson's program and scaling its product Nugevia™, which is generating commercial cash flow [3] Commercial Performance - Jupiter's strategy combines clinical development with active commercial revenue generation, with Nugevia™ showing repeat purchase activity of approximately 25% and product return rates of about 3% [3] - The company believes that early commercial validation, along with continued clinical progress, strengthens its capital profile and differentiates it from biotechnology peers reliant solely on capital markets funding [3] Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and central nervous system disorders, with its lead clinical program in a Phase IIa trial for Parkinson's disease [5] - The company is also commercializing Nugevia™, a consumer product based on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability [5]

Core Insights - Jupiter Neurosciences, Inc. is launching a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ product line, which focuses on metabolic, mitochondrial, and neuroinflammatory health [1][2] Group 1: Company Strategy - The company is pursuing a dual-engine strategy that combines a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business, aiming to capitalize on the growing adoption of GLP-1 therapies globally [2] - Jupiter believes that the physiological demands placed on individuals undergoing GLP-1-induced weight loss represent an unmet need, as many seek solutions for long-term metabolic resilience and healthspan [3] Group 2: Product Development - The Nugevia product line is designed to address the biological stresses associated with rapid metabolic changes, particularly focusing on mitochondrial health, neuroinflammation, and cellular resilience [4] - Jupiter's proprietary formulation, JOTROL, enhances the bioavailability of resveratrol and supports mental clarity, skin health, and mitochondrial function, positioning Nugevia as a clinical-grade supplement [5] Group 3: Market Context - The rise of GLP-1 receptor agonists has significantly transformed the landscape of obesity and metabolic health, with increasing awareness of the physiological impacts of weight loss on individuals [3] - The Aesthetic Surgery Journal reported that patients with significant weight loss may appear up to 5 years older than their peers, highlighting the need for supportive solutions like Nugevia [4]

Core Viewpoint - Jupiter Neurosciences, Inc. is hosting a webinar to discuss its scientific platform, clinical development plans, and commercial strategy for 2026, focusing on its lead asset JOTROL™ and its dual-path approach in both pharmaceutical and consumer markets [2][4]. Group 1: Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company targeting neuroinflammation and healthy aging through a dual-path strategy [4]. - The company is advancing a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [4]. - JOTROL™, a proprietary enhanced resveratrol formulation, has shown significantly improved bioavailability compared to earlier resveratrol products [4][5]. Group 2: JOTROL™ and Clinical Development - JOTROL™ achieves over nine times higher bioavailability compared to previous resveratrol formulations, which is critical for its effectiveness [6]. - The company is advancing JOTROL™ toward a Phase IIa clinical trial in Parkinson's Disease, with a broader focus on CNS disorders including Alzheimer's Disease and Friedreich's Ataxia [4][6]. - The Phase I study results of JOTROL™ were published in reputable journals, indicating a strong foundation for upcoming trials [6]. Group 3: Nugevia Product Line - Nugevia™ is a premium longevity and performance supplement line that utilizes the same patented JOTROL™ technology, targeting cognitive health, skin vitality, and cellular energy [8][9]. - Nugevia products are developed under pharmaceutical standards and are based on peer-reviewed clinical data, differentiating them from conventional supplements [9]. - The product line aims to support healthy aging through formulations that enhance cognitive resilience, mitochondrial energy, and skin vitality [8].

Core Viewpoint - Jupiter Neurosciences, Inc. has announced the addition of Chris Webber as the second brand ambassador for its new longevity supplement line, Nugevia™, which is based on clinical science and innovative performance-driven technology [1][3]. Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy that includes advancing therapeutics for CNS disorders and entering the consumer longevity market with Nugevia™ [7]. - The company’s proprietary JOTROL™ platform enhances the bioavailability of resveratrol, which is the foundation for both its therapeutic pipeline and the Nugevia™ product line [10]. Product Details - Nugevia™ features three initial formulations—GLO, MND, and PWR—designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL™ system [4]. - The Nugevia™ brand aims to tap into the rapidly growing longevity market, projected to reach $8 trillion by 2030, creating a revenue stream to support ongoing clinical development and enhance long-term shareholder value [5][6]. Scientific Validation - JOTROL™ has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, as evidenced by a Phase I study published in reputable journals [9]. - The technology aims to provide pharmaceutical-grade bioavailability in the wellness space, targeting cognitive health, skin vitality, and cellular energy [10].

Core Insights - Jupiter Neurosciences, Inc. has officially launched Nugevia™, a consumer longevity product line, marking a significant milestone in its strategy to generate near-term revenue while advancing its clinical pipeline [1][5] - The launch of Nugevia responds to the growing global demand for scientifically validated wellness solutions aimed at extending healthspan and enhancing mental and metabolic resilience [2][4] - Nugevia's formulations utilize Jupiter's proprietary JOTROL technology, which has demonstrated a 9x improvement in bioavailability compared to traditional resveratrol products [3][9] Product Details - Nugevia's initial offerings focus on mitochondrial support, mental clarity, and "beauty from within," and will be marketed through a direct-to-consumer model starting in Q3 2025 [3][5] - The product line features "intelligent stacking" of synergistic compounds designed to enhance cellular resilience and promote system-wide optimization [4] - JOTROL is the foundation of both the Nugevia product line and ongoing therapeutic programs targeting CNS disorders such as Parkinson's and Alzheimer's disease [3][7] Strategic Implications - The launch of Nugevia is positioned as a strategic engine for growth, providing a near-term revenue stream that supports ongoing clinical trials and enhances long-term shareholder value [5][6] - The longevity market is projected to reach $8 trillion by 2030, indicating significant commercial potential for Nugevia and aligning with the company's dual-path strategy of advancing clinical therapies while monetizing its platform [5][6] - The integration of consumer products with clinical research is expected to create a self-reinforcing commercial engine, benefiting both the company's therapeutic pipeline and its business model [5][6]